Auxly Announces Strategic Agreement with Lonza for Liquid Filled Capsules and Fill and Seal Technology
June 19 2019 - 8:00AM
Auxly Cannabis Group Inc. (TSX.V - XLY)
("
Auxly") is pleased to announce that Auxly’s
wholly owned subsidiary, Dosecann Inc.
(“
Dosecann”) has entered into a definitive
agreement with Capsugel Inc., a subsidiary of Lonza Group Ltd.
(“
Capsugel”), to provide Dosecann with a complete
line of equipment for capsule filling and sealing, including a
state-of-the-art LEMS® machine, Lonza’s proprietary liquid-filled
Capsugel® Licaps® capsules, and rights to its capsule filling and
sealing LEMS® technology. In addition, Dosecann and Lonza will work
collaboratively on new product formulation for cannabis capsule
products.
Lonza’s technology is currently used for several
functional improvements in health and nutritional applications,
including bioavailability enhancement, taste and odor masking,
combination products, and controlled and delayed release. With the
licensed technology, Dosecann’s PEI facility will be equipped with
a full manufacturing line with the capacity to fill and seal up to
200 million Capsugel® Licaps® capsules per year and the ability to
deliver new compounds with improved functionality. Access to
Lonza’s patented technologies will enhance Dosecann’s product
development and manufacturing capabilities and support
differentiated product offerings through multiple delivery systems
and colour and branding possibilities. With these technologies,
Dosecann will be able to bring to market a variety of innovative,
differentiated capsule products across a wide range of dosage
forms.
“We are very excited to be working in concert
with a global leader in capsules and encapsulation technology and
look forward to building a creative and fruitful relationship with
the Lonza/Capsugel team.” says Hugo Alves, President of Auxly. “The
timing is also ideal as we prepare for the derivative products
market once those products are legally permitted later this year.
Access to Lonza’s technology provides us with innovative delivery
solutions for our science-backed cannabis derivative products.
Equally as exciting, Dosecann’s incredible science team will
collaborate with Lonza to develop enhanced formulations so that we
can offer consumers a suite of high quality, effective products and
position Auxly as a leader in the capsule product category.”
ON BEHALF OF THE BOARD"Chuck Rifici" Chairman
& CEO
About Auxly Cannabis Group Inc. (TSX.V:
XLY) (OTCQX: CBWTF)
Auxly is an international cannabis company
dedicated to bringing innovative, effective, and high-quality
cannabis products to the medical, wellness and adult-use markets.
Auxly's experienced team of industry first-movers and enterprising
visionaries has secured a diversified supply of raw cannabis,
strong clinical, scientific and operating capabilities and leading
research and development infrastructure in order to create trusted
products and brands in an expanding global market.Learn more at
www.auxly.com and stay up to date at Twitter:
@AuxlyGroup; Instagram: @auxlygroup; Facebook:
@auxlygroup; LinkedIn: company/auxlygroup/.
Investor Relations:For investor
enquiries please contact our Investor Relations Team: Email:
IR@auxly.comPhone: 1.833.695.2414
Media Enquiries
(only): For media enquiries or to set up an interview
please contact:Sarah Bain, VP External Affairs Email:
sarah@auxly.com Phone: 613.230.5869
Notice Regarding Forward Looking
Information:
This news release contains certain
"forward-looking information" within the meaning of applicable
Canadian securities law. Forward-looking information is frequently
characterized by words such as "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed" and other similar words, or
information that certain events or conditions "may" or "will"
occur. This information is only a prediction. Various assumptions
were used in drawing the conclusions or making the projections
contained in the forward-looking information throughout this news
release. Forward-looking information includes, but is not limited
to: the proposed operation of Dosecann’s facility, political
change, future legislative and regulatory developments involving
cannabis and cannabis products; and competition and other risks
affecting Auxly and Dosecann in particular and the cannabis
industry generally.
A number of factors could cause actual results
to differ materially from a conclusion, forecast or projection
contained in the forward-looking information in this release
including, but not limited to whether: Dosecann is able to obtain
and maintain the necessary regulatory authorizations to conduct
business, Dosecann is able to obtain and maintain all necessary
governmental and regulatory permits and approvals for the operation
of its facility and the development of its proposed products, and
general economic, financial market, regulatory and political
conditions in which Auxly and Dosecann operate will remain the
same. Additional risk factors are disclosed in the revised annual
information form of Auxly for the financial year ended December 31,
2017 dated May 24, 2018.
New factors emerge from time to time, and it is
not possible for management to predict all of those factors or to
assess in advance the impact of each such factor on Auxly’s
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking information. The forward-looking
information in this release is based on information currently
available and what management believes are reasonable assumptions.
Forward-looking information speaks only to such assumptions as of
the date of this release. In addition, this release may contain
forward-looking information attributed to third party industry
sources, the accuracy of which has not been verified by Auxly. The
purpose of forward-looking information is to provide the reader
with a description of management's expectations, and such
forward-looking information may not be appropriate for any other
purpose. Readers should not place undue reliance on forward-looking
information contained in this release.
The forward-looking information contained in
this release is expressly qualified by the foregoing cautionary
statements and is made as of the date of this release. Except as
may be required by applicable securities laws, Auxly does not
undertake any obligation to publicly update or revise any
forward-looking information to reflect events or circumstances
after the date of this release or to reflect the occurrence of
unanticipated events, whether as a result of new information,
future events or results, or otherwise.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Auxly Cannabis (TSXV:XLY)
Historical Stock Chart
From Apr 2024 to May 2024
Auxly Cannabis (TSXV:XLY)
Historical Stock Chart
From May 2023 to May 2024